Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, De Guibert S, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G.

Ann Oncol. 2019 Oct 4. pii: mdz407. doi: 10.1093/annonc/mdz407. [Epub ahead of print]

PMID:
31584608
2.

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C.

Lung Cancer. 2019 Oct;136:109-114. doi: 10.1016/j.lungcan.2019.08.010. Epub 2019 Aug 14.

PMID:
31491676
3.

Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients.

Jouinot A, Ulmann G, Vazeille C, Durand JP, Boudou-Rouquette P, Arrondeau J, Tlemsani C, Fournel L, Alifano M, Wislez M, Chapron J, Le Bris C, Mansuet-Lupo A, Damotte D, Neveux N, De Bandt JP, Alexandre J, Cynober L, Goldwasser F.

Clin Nutr. 2019 Aug 10. pii: S0261-5614(19)30315-2. doi: 10.1016/j.clnu.2019.08.003. [Epub ahead of print]

PMID:
31443979
4.

Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?

Mignard X, Ruppert AM, Lavolé A, Vieira T, Rozensztajn N, Cadranel J, Wislez M.

Bull Cancer. 2019 Sep;106(9):725-733. doi: 10.1016/j.bulcan.2019.04.010. Epub 2019 Jun 13.

PMID:
31202557
5.

Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.

Jamme P, Descarpentries C, Gervais R, Dansin E, Wislez M, Grégoire V, Richard N, Baldacci S, Rabbe N, Kyheng M, Kherrouche Z, Escande F, Copin MC, Cortot AB.

Clin Lung Cancer. 2019 Jul;20(4):297-304.e1. doi: 10.1016/j.cllc.2019.02.013. Epub 2019 Feb 26.

PMID:
31147208
6.

Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial.

Puéchal X, Pagnoux C, Baron G, Lifermann F, Geffray L, Quémeneur T, Saraux JL, Wislez M, Cottin V, Ruivard M, Limal N, Aouba A, Bonnotte B, Néel A, Agard C, Cohen P, Terrier B, Le Jeunne C, Mouthon L, Ravaud P, Guillevin L; French Vasculitis Study Group investigators.

Rheumatology (Oxford). 2019 May 5. pii: kez139. doi: 10.1093/rheumatology/kez139. [Epub ahead of print]

PMID:
31056661
7.

Nivolumab-refractory patients with advanced non-small-cell lung cancer.

Costantini A, Fallet V, Corny J, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Brosseau S, Wislez M, Tredaniel J, Cadranel J.

Lung Cancer. 2019 Apr;130:128-134. doi: 10.1016/j.lungcan.2019.01.015. Epub 2019 Feb 14.

PMID:
30885333
8.

Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors.

Mansuet-Lupo A, Barritault M, Alifano M, Janet-Vendroux A, Zarmaev M, Biton J, Velut Y, Le Hay C, Cremer I, Régnard JF, Fournel L, Rance B, Wislez M, Laurent-Puig P, Herbst R, Damotte D, Blons H.

J Thorac Oncol. 2019 May;14(5):844-856. doi: 10.1016/j.jtho.2019.01.017. Epub 2019 Feb 2.

PMID:
30721797
9.

Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma.

Ruppert AM, Baud L, Rabbe N, Perez J, Duruisseaux M, Vieira T, Antoine M, Cadranel J, Wislez M.

Bull Cancer. 2019 Mar;106(3):179-188. doi: 10.1016/j.bulcan.2018.11.014. Epub 2019 Jan 23.

PMID:
30683309
10.

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C.

Lung Cancer. 2019 Jan;127:96-102. doi: 10.1016/j.lungcan.2018.11.037. Epub 2018 Nov 27.

PMID:
30642559
11.

[Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer].

Bay JO, André T, Caux C, Evrard S, Gonçalves A, L'Allemain G, Magné N, Orbach D, Penel N, Rodrigues M, Thariat J, Thiery-Vuillemin A, Wislez M; Comité de Rédaction du Bulletin du Cancer.

Bull Cancer. 2019 Jan;106(1):12-23. doi: 10.1016/j.bulcan.2018.12.005. Epub 2019 Jan 3. Review. French.

PMID:
30612698
12.

Actualités et perspectives concernant l’immunothérapie en oncologie thoracique.

Mignard X, Chaabane N, Fallet V, Wislez M.

Bull Cancer. 2018 Dec;105 Suppl 1:S16-S23. doi: 10.1016/S0007-4551(18)30386-2. Review. French.

PMID:
30595194
13.

Regulator of telomere length 1 (RTEL1) mutations are associated with heterogeneous pulmonary and extra-pulmonary phenotypes.

Borie R, Bouvry D, Cottin V, Gauvain C, Cazes A, Debray MP, Cadranel J, Dieude P, Degot T, Dominique S, Gamez AS, Jaillet M, Juge PA, Londono-Vallejo A, Mailleux A, Mal H, Boileau C, Menard C, Nunes H, Prevot G, Quetant S, Revy P, Traclet J, Wemeau-Stervinou L, Wislez M, Kannengiesser C, Crestani B.

Eur Respir J. 2019 Feb 7;53(2). pii: 1800508. doi: 10.1183/13993003.00508-2018. Print 2019 Feb.

PMID:
30523160
14.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M.

Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19. Review. French.

PMID:
30343945
15.

[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].

Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D.

Rev Pneumol Clin. 2018 Oct;74(5):339-350. doi: 10.1016/j.pneumo.2018.09.010. Epub 2018 Oct 15. Review. French.

PMID:
30337201
16.

[Data from the AACR 2018 meeting on the combination chimio-immunotherapy on advanced non-small cells lung cancer (NSCLC)].

Simonneau Y, Ruppert AM, Chaabane N, Lavolé A, Wislez M.

Bull Cancer. 2018 Oct;105(10):854-856. doi: 10.1016/j.bulcan.2018.07.016. Epub 2018 Sep 24. French. No abstract available.

PMID:
30262415
17.

[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].

Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M.

Rev Mal Respir. 2018 Nov;35(9):983-988. doi: 10.1016/j.rmr.2018.08.006. Epub 2018 Sep 20. French.

18.

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].

Baldacci S, Kherrouche Z, Descarpentries C, Wislez M, Dansin E, Furlan A, Tulasne D, Cortot AB.

Rev Mal Respir. 2018 Oct;35(8):796-812. doi: 10.1016/j.rmr.2018.01.011. Epub 2018 Aug 31. Review. French.

PMID:
30174236
19.

c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.

Mignard X, Ruppert AM, Antoine M, Vasseur J, Girard N, Mazières J, Moro-Sibilot D, Fallet V, Rabbe N, Thivolet-Bejui F, Rouquette I, Lantuejoul S, Cortot A, Saffroy R, Cadranel J, Lemoine A, Wislez M.

J Thorac Oncol. 2018 Dec;13(12):1962-1967. doi: 10.1016/j.jtho.2018.08.008. Epub 2018 Aug 24.

20.

Lung cancer and interstitial lung disease: a literature review.

Naccache JM, Gibiot Q, Monnet I, Antoine M, Wislez M, Chouaid C, Cadranel J.

J Thorac Dis. 2018 Jun;10(6):3829-3844. doi: 10.21037/jtd.2018.05.75. Review.

21.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.

Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.

PMID:
29764856
22.

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer.

Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Nguenang M, Jouveshomme S, Wislez M, Tredaniel J, Cadranel J.

ERJ Open Res. 2018 Apr 20;4(2). pii: 00120-2017. doi: 10.1183/23120541.00120-2017. eCollection 2018 Apr.

23.

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.

Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).

Eur Respir J. 2018 Mar 15;51(3). pii: 1701467. doi: 10.1183/13993003.01467-2017. Print 2018 Mar.

24.

Alectinib in untreated anaplastic lymphoma kinase-positive non-small cell lung cancer.

Ruppert AM, Mignard X, Wislez M.

Ann Transl Med. 2017 Dec;5(23):460. doi: 10.21037/atm.2017.09.05. No abstract available.

25.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Baldacci S, Mazieres J, Tomasini P, Girard N, Guisier F, Audigier-Valette C, Monnet I, Wislez M, Pérol M, Dô P, Dansin E, Leduc C, Giroux Leprieur E, Moro-Sibilot D, Tulasne D, Kherrouche Z, Labreuche J, Cortot AB.

Oncotarget. 2017 Oct 9;8(62):105103-105114. doi: 10.18632/oncotarget.21707. eCollection 2017 Dec 1.

26.

[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].

Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L'Allemain G, Bay JO.

Bull Cancer. 2018 Jan;105(1):6-14. doi: 10.1016/j.bulcan.2017.11.006. Review. French.

PMID:
29269176
27.

[Lung cancer in HIV-infected patients].

Domblides C, Canellas A, Wislez M, Fallet V, Antoine M, Crequit P, Cadranel J, Lavolé A.

Bull Cancer. 2018 Jan;105(1):111-119. doi: 10.1016/j.bulcan.2017.11.002. Epub 2017 Dec 22. Review. French.

PMID:
29269175
28.

Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer.

Giroux Leprieur E, Tolani B, Li H, Leguay F, Hoang NT, Acevedo LA, Jin JQ, Tseng HH, Yue D, Kim IJ, Wislez M, Wang C, Jablons DM, He B.

Oncotarget. 2017 Oct 10;8(61):103744-103757. doi: 10.18632/oncotarget.21781. eCollection 2017 Nov 28.

29.

Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates.

Domblides C, Antoine M, Hamard C, Rabbe N, Rodenas A, Vieira T, Crequit P, Cadranel J, Lavolé A, Wislez M.

AIDS. 2018 Feb 20;32(4):461-468. doi: 10.1097/QAD.0000000000001713.

PMID:
29194117
30.

Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma.

Duruisseaux M, Rabbe N, Antoine M, Vieira T, Poulot V, Cadranel J, Wislez M.

ERJ Open Res. 2017 Mar 31;3(1). pii: 00047-2016. doi: 10.1183/23120541.00047-2016. eCollection 2017 Jan.

31.

[Toward new modalities of surveillance in lung cancer patients?]

Domblides C, Chaabane N, Wislez M.

Bull Cancer. 2017 Sep;104(9):703-704. doi: 10.1016/j.bulcan.2017.07.004. Epub 2017 Aug 8. French. No abstract available.

PMID:
28801133
32.

Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis.

Sesé L, Nunes H, Cottin V, Sanyal S, Didier M, Carton Z, Israel-Biet D, Crestani B, Cadranel J, Wallaert B, Tazi A, Maître B, Prévot G, Marchand-Adam S, Guillot-Dudoret S, Nardi A, Dury S, Giraud V, Gondouin A, Juvin K, Borie R, Wislez M, Valeyre D, Annesi-Maesano I.

Thorax. 2018 Feb;73(2):145-150. doi: 10.1136/thoraxjnl-2017-209967. Epub 2017 Aug 10.

PMID:
28798214
33.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Tomasini P, Brosseau S, Mazières J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700514. doi: 10.1183/13993003.00514-2017. Print 2017 Aug.

34.

Lymphoproliferative Disorders of the Lung.

Borie R, Wislez M, Antoine M, Cadranel J.

Respiration. 2017;94(2):157-175. doi: 10.1159/000477740. Epub 2017 Jun 14. Review.

35.

Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.

Duruisseaux M, Antoine M, Rabbe N, Rodenas A, Mc Leer-Florin A, Lacave R, Poulot V, Duchêne B, Van Seuningen I, Cadranel J, Wislez M.

Lung Cancer. 2017 Jul;109:92-100. doi: 10.1016/j.lungcan.2017.05.007. Epub 2017 May 10.

PMID:
28577958
36.

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E.

Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.

37.

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.

Lim JS, Ibaseta A, Fischer MM, Cancilla B, O'Young G, Cristea S, Luca VC, Yang D, Jahchan NS, Hamard C, Antoine M, Wislez M, Kong C, Cain J, Liu YW, Kapoun AM, Garcia KC, Hoey T, Murriel CL, Sage J.

Nature. 2017 May 18;545(7654):360-364. doi: 10.1038/nature22323. Epub 2017 May 10.

38.

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities.

Pécuchet N, Vieira T, Rabbe N, Antoine M, Blons H, Cadranel J, Laurent-Puig P, Wislez M.

Ann Oncol. 2017 Jul 1;28(7):1597-1604. doi: 10.1093/annonc/mdx162.

PMID:
28419182
39.

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.

Saffroy R, Fallet V, Girard N, Mazieres J, Sibilot DM, Lantuejoul S, Rouquette I, Thivolet-Bejui F, Vieira T, Antoine M, Cadranel J, Lemoine A, Wislez M.

Oncotarget. 2017 Jun 27;8(26):42428-42437. doi: 10.18632/oncotarget.16403.

40.

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank.

Stücker I, Martin D, Neri M, Laurent-Puig P, Blons H, Antoine M, Guiochon-Mantel A, Brailly-Tabard S, Canonico M, Wislez M, Trédaniel J; WELCA study group.

BMC Public Health. 2017 Apr 17;17(1):324. doi: 10.1186/s12889-017-4191-1.

41.

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

Cortot AB, Kherrouche Z, Descarpentries C, Wislez M, Baldacci S, Furlan A, Tulasne D.

J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djw262. Review.

PMID:
28376232
42.

[Crizotinib for ROS1-rearranged non-small cell lung cancer patients].

Domblides C, Antoine M, Lavole A, Cadranel J, Wislez M.

Bull Cancer. 2017 Apr;104(4):303-310. doi: 10.1016/j.bulcan.2017.01.008. Epub 2017 Feb 22. French.

PMID:
28237354
43.

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives.

Giroux-Leprieur E, Fallet V, Cadranel J, Wislez M.

Lung Cancer (Auckl). 2016 Jun 17;7:83-90. doi: 10.2147/LCTT.S99303. eCollection 2016. Review.

44.

[Diagnostic and therapeutic strategy in lung cancer].

Rozensztajn N, Créquit P, Wislez M, Cadranel J.

Rev Prat. 2017 Jan;67(1):40-46. French.

PMID:
30512432
45.

[Which recent results in Oncology and Hematology will have an impact on our practices? The point of vue of Bulletin du Cancer editorial board].

Vignot S, André T, Gonçalves A, Guièze R, Magné N, Orbach D, Penel N, Thariat J, Wislez M, Bay JO.

Bull Cancer. 2017 Jan;104(1):6-19. doi: 10.1016/j.bulcan.2016.11.009. Epub 2016 Dec 19. Review. French.

PMID:
28007296
46.

[Perioperative therapies in surgical non N2 non-small cell lung cancer].

Ruppert AM, Lavolé A, Assouad J, Cadranel J, Wislez M.

Bull Cancer. 2017 Jan;104(1):79-85. doi: 10.1016/j.bulcan.2016.10.017. Epub 2016 Nov 29. Review. French.

PMID:
27912893
47.

[Osimertinib (Tagrisso®): Activity, indication and modality of use in non-small cell lung cancer].

Giroux Leprieur E, Cortot AB, Cadranel J, Wislez M.

Bull Cancer. 2016 Oct;103(10):815-821. doi: 10.1016/j.bulcan.2016.06.007. Epub 2016 Sep 15. French.

PMID:
27641462
48.

[Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].

Pellat A, Wislez M, Svrcek M, Hammel P, Afchain P, André T.

Bull Cancer. 2016 Oct;103(10):880-895. doi: 10.1016/j.bulcan.2016.06.006. Epub 2016 Aug 6. French.

PMID:
27507031
49.

NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.

Duruisseaux M, McLeer-Florin A, Antoine M, Alavizadeh S, Poulot V, Lacave R, Rabbe N, Cadranel J, Wislez M.

Cancer Med. 2016 Dec;5(12):3579-3585. doi: 10.1002/cam4.838. Epub 2016 Oct 21.

50.

Pulmonary mucosa-associated lymphoid tissue lymphoma revisited.

Borie R, Wislez M, Antoine M, Copie-Bergman C, Thieblemont C, Cadranel J.

Eur Respir J. 2016 Oct;48(4):1252. doi: 10.1183/13993003.01143-2016. No abstract available.

Supplemental Content

Loading ...
Support Center